LinkGevity

science

Blueprint Theory of aging

At LinkGevity, we embrace a pioneering approach to aging. Spearheaded by our CEO, Dr. Carina Kern, the Blueprint Theory provides a transformative framework illuminating the intricate "triggers" underlying aging and deterioration. By leveraging the power of the Blueprint, we uncover the fundamental drivers of age-related diseases, enabling us to intervene in ways previously unimaginable.

Our Blueprint Theory uncovers triggered molecular pathways that, for the first time, causally explain the origins of aging and age-related disease. At LinkGevity, we are dedicated to systematically translating this science into therapeutics that help people stay healthy for longer.

Platform

Computationally solving the complexity of aging

Our AI-powered platform leverages semantic processing to reclassify vast amounts of biomedical data according to the Blueprint Theory. The resulting technology can not only identify new therapeutic targets but also holds the potential for accurate risk factor analysis and disease prediction.

Power of AI

By harnessing the power of AI, we are constructing comprehensive Blueprint Maps that unveil the intricate triggers of aging at every level of biological hierarchy. From cellular dynamics to organ function, our approach allows us to decipher the language of healthspan, offering unprecedented insights into the mechanisms that shape the aging process.

APPLICATION

Finding new drug classes

At LinkGevity, our groundbreaking discovery of Anti-Necrotics™ marks a monumental leap forward in our quest to redefine the boundaries of health and longevity. By inhibiting necrosis, we are not only enhancing cellular resilience and fortifying cells against stress, but also paving the way for game-changing treatments in the clinic, starting with Acute Kidney Injury.

This is just the beginning of our journey toward unlocking the full potential of our therapeutics, with the promise of transforming the landscape of healthcare for generations to come.

Our innovation does not stop there. Necrosis has long been a formidable obstacle in organ preservation and tissue engineering, stumping scientists. Armed with our technology and guided by our Blueprint approach, we are poised to revolutionize these areas as well.